DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

Status Completed

Clinical Trial Summary

This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma. Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

Clinical Trial Description

OBJECTIVES: I. To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies. II. To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors. III. To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy. OUTLINE: This is a multicenter study. Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01190943
Study type	Observational
Source	Children's Oncology Group
Contact
Status	Completed
Phase
Start date	August 6, 2010

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06041490` - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	Phase 2
Not yet recruiting	`NCT05515068` - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed	`NCT00093821` - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors	Phase 1
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT01553539` - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00091182` - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Phase 2
Completed	`NCT00004078` - Irinotecan in Treating Children With Refractory Solid Tumors	Phase 2
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Active, not recruiting	`NCT04284774` - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03213678` - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT04668300` - Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	Phase 2
Completed	`NCT02470091` - Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma	Phase 2
Completed	`NCT01016015` - Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2
Completed	`NCT01807052` - Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas	N/A
Active, not recruiting	`NCT03698994` - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Not yet recruiting	`NCT03205644` - VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04320888` - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Completed	`NCT00030667` - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood	Phase 2